Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GLS | O94925 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CTSA | P10619 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31736245 | 1.00 | LMNA (0.59) | LMNAMAPK1ALDH1A1GLSIDO1 | |
| SCHEMBL742997 | 1.00 | LMNA (0.59) | LMNAMAPK1ALDH1A1GLSIDO1 | |
| SCHEMBL31038341 | 1.00 | LMNA (0.59) | LMNAMAPK1ALDH1A1GLSIDO1 | |
| SCHEMBL742998 | 1.00 | LMNA (0.59) | LMNAMAPK1ALDH1A1GLSIDO1 | |
| SCHEMBL276569 | 0.85 | LMNA (0.73) | LMNAMAPK1BLMNPSR1TSHR | |
| SCHEMBL20930558 | 0.83 | CYP2D6 (0.60) | LMNAMAPK1ALDH1A1IDO1TDO2 | |
| SCHEMBL4530990 | 0.82 | ALDH1A1 (0.44) | MAPK1ALDH1A1GLSIDO1TDO2 | |
| SCHEMBL11217020 | 0.82 | GLS (0.44) | LMNAMAPK1ALDH1A1GLSIDO1 | |
| SCHEMBL23174036 | 0.82 | CES2 (0.67) | LMNAMAPK1ALDH1A1GLSIDO1 | |
| SCHEMBL5856096 | 0.82 | SRC (0.58) | LMNAMAPK1ALDH1A1IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124909-A1 | NOVEL PROCESS | GENERICS [UK] LIMITED (GB) | 2011-05-26 | — | — | US | claimed |
| EP-2262761-A1 | NOVEL PROCESS | Generics [UK] Limited (GB) | 2010-12-22 | — | — | EP | claimed |
| WO-2009122215-A1 | NOVEL PROCESS | GENERICS [UK] LIMITED (GB) | 2009-10-08 | — | — | WO | claimed |
| CN-115427409-B | Pyrimidine-4 (3H) -one derivatives as TRPV4 antagonists | 拉夸里亚创药株式会社 | 2025-02-25 | — | — | CN | disclosed |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| WO-2021221169-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2021-11-04 | — | — | WO | disclosed |
| US-10857517-B2 | Porous chiral materials and uses thereof | NANKAI UNIVERSITY (CN) | 2020-12-08 | — | — | US | disclosed |
| US-9315792-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2016-04-19 | — | — | US | disclosed |
| US-9217164-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2015-12-22 | — | — | US | disclosed |
| EP-2327766-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-12-02 | — | — | EP | disclosed |
| US-20090176976-A1 | Increased activity and stability at increased pH and temperature | VERENIUM CORPORATION | 2009-07-09 | — | — | US | disclosed |
| US-20090176976-A1 | Increased activity and stability at increased pH and temperature | VERENIUM CORPORATION | 2009-07-09 | — | — | US | disclosed |
| US-7521216-B2 | Nitrilases and methods for making and using them | VERENIUM CORPORATION (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521216-B2 | Nitrilases and methods for making and using them | VERENIUM CORPORATION (US) | 2009-04-21 | — | — | US | disclosed |
| EP-2039762-A2 | Nitralases | Verenium Corporation (US) | 2009-03-25 | — | — | EP | disclosed |
| US-4297489-A | CEPHALOSPORINS | BRISTOL-MYERS COMPANY (US) | 1981-10-27 | — | — | US | disclosed |
| US-4172196-A | CEPHALOSPORINS | BRISTOL-MYERS COMPANY (US) | 1979-10-23 | — | — | US | disclosed |
| US-4112228-A | BACTERICIDES | BRISTOL-MYERS COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-3985738-A | ANTIBACTERIAL AGENTS | BRISTOL-MYERS COMPANY (US) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | TRPV4, TRPV1, TRPV2 | LMNA 4199/4885MAPK1 1813/4885ALDH1A1 1663/4885 |
| US-20110124909-A1 | NOVEL PROCESS | GABRE, GABRB2, GABRB1 | LMNA 3715/4885MAPK1 3278/4885ALDH1A1 1268/4885 |
| US-10857517-B2 | Porous chiral materials and uses thereof | ANXA7, XDH, OPRM1 | LMNA 219/4885MAPK1 1200/4885ALDH1A1 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.